



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/955,373	10/21/1997	SOREN MOURITSEN	2473.0570003/EKS/LMB	7254
26111 7590 12/18/2007 STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. 1100 NEW YORK AVENUE, N.W. WASHINGTON, DC 20005			EXAMINER SCHWADRON, RONALD B	
			ART UNIT 1644	PAPER NUMBER
			MAIL DATE 12/18/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	Application No. 08/955,373	Applicant(s) MOURITSEN ET AL.	
	Examiner Ron Schwadron, Ph.D.	Art Unit 1644	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 85-101 is/are pending in the application.  
     4a) Of the above claim(s) 88-100 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 85-87, 101 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
     a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____.  |

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/31/07 has been entered.

2. Claims 85-87,101 are under consideration.

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 85-87,101 stand rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicants arguments have been considered and deemed not persuasive.

The specification does not provide adequate written description of the claimed invention. The legal standard for sufficiency of a patent's (or a specification's) written description is whether that description "reasonably conveys to the artisan that the inventor had possession at that time of the . . . claimed subject matter", *Vas-Cath, Inc. V. Mahurkar*, 19 U.S.P.Q.2d 1111 (Fed. Cir. 1991). In the instant case, the specification does not convey to the artisan that the applicant had possession at the time of invention of the claimed invention.

The instant claims encompass a method that uses a mutant analogue peptide wherein the analogue peptide has a substituted foreign immunodominant T cell epitope with

the functional properties recited in the claim. Whilst the specification discloses a particular example of a particular molecule with a particular substitution which apparently has the properties recite in the claims, the claims encompass a vast collection of mutant molecules with the properties recited in the claims that are not disclosed in the specification. It is unpredictable as to what particular substitutions can be made to any particular molecule and result in a mutant analogue molecule with the functional attributes recited in the claims.

In view of the aforementioned problems regarding description of the claimed invention, the specification does not provide an adequate written description of the invention claimed herein. See *The Regents of the University of California v. Eli Lilly and Company*, 43 USPQ2d 1398, 1404-7 (Fed. Cir. 1997). In *University of California v. Eli Lilly and Co.*, 39 U.S.P.Q.2d 1225 (Fed. Cir. 1995) the inventors claimed a genus of DNA species encoding insulin in different vertebrates or mammals, but had only described a single species of cDNA which encoded rat insulin. The court held that only the nucleic acids species described in the specification (i.e. nucleic acids encoding rat insulin) met the description requirement and that the inventors were not entitled to a claim encompassing a genus of nucleic acids encoding insulin from other vertebrates, mammals or humans, *id.* at 1240. In the instant case, the facts are similar to those disclosed in *University of California v. Eli Lilly and Co.* The Federal Circuit has held that if an inventor is "unable to envision the detailed constitution of a gene so as to distinguish it from other materials. . .conception has not been achieved until reduction to practice has occurred", *Amgen, Inc. v. Chugai Pharmaceutical Co, Ltd.*, 18 U.S.P.Q.2d 1016 (Fed. Cir. 1991). Attention is also directed to the decision of *The Regents of the University of California v. Eli Lilly and Company* (CAFC, July 1997) wherein is stated: The description requirement of the patent statute requires a description of an invention, not an indication of a result that one might achieve if one made that invention. See *In re Wilder*, 736 F.2d 1516, 222 USPQ 369, 372-373 (Fed. Cir. 1984) (affirming rejection because the specification does "little more than outlin[e] goals appellants hope the claimed invention achieves and the problems the invention

will hopefully ameliorate." ). Accordingly, naming a type of material generally known to exist, in the absence of knowledge as to what that material consists of, is not a description of that material. Thus, as we have previously held, a cDNA is not defined or described by the mere name "cDNA," even if accompanied by the name of the protein that it encodes, but requires a kind of specificity usually achieved by means of the recitation of the sequence of nucleotides that make up the cDNA. See *Fiers*, 984 F.2d at 1171, 25 USPQ2d at 1606.

Regarding applicants comments, the instant claims encompass a method that uses a mutant analogue peptide wherein the analogue peptide has a substituted foreign immunodominant T cell epitope with the functional properties recited in the claim. Whilst the specification discloses a particular example of a particular molecule with a particular substitution which apparently has the properties recite in the claims, the claims encompass a vast collection of mutant molecules with the properties recited in the claims that are not disclosed in the specification. It is unpredictable as to what particular substitutions can be made to any particular molecule and result in a mutant analogue molecule with the functional attributes recited in the claims. In *University of California v. Eli Lilly and Co.*, 39 U.S.P.Q.2d 1225 (Fed. Cir. 1995) the inventors claimed a genus of DNA species encoding insulin in different vertebrates or mammals, but had only described a single species of cDNA which encoded rat insulin. The court held that only the nucleic acids species described in the specification (i.e. nucleic acids encoding rat insulin) met the description requirement and that the inventors were not entitled to a claim encompassing a genus of nucleic acids encoding insulin from other vertebrates, mammals or humans, *id.* at 1240. In the instant case, the facts are similar to those disclosed in *University of California v. Eli Lilly and Co.* The Federal Circuit has held that if an inventor is "unable to envision the detailed constitution of a gene so as to distinguish it from other materials. . .conception has not been achieved until reduction to practice has occurred", *Amgen, Inc. v. Chugai Pharmaceutical Co, Ltd.*, 18 U.S.P.Q.2d 1016 (Fed. Cir. 1991). Attention is also directed to the decision of *The Regents of the University of California v. Eli Lilly and Company* (CAFC, July 1997)

wherein is stated: The description requirement of the patent statute requires a description of an invention, not an indication of a result that one might achieve if one made that invention. See *In re Wilder*, 736 F.2d 1516, 222 USPQ 369, 372-373 (Fed. Cir. 1984) (affirming rejection because the specification does "little more than outlin[e] goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate."). Regarding applicants comments about screening methods, the MPEP section 2163, II.A.3.(a) states:

*An adequate written description of a chemical invention also requires a precise definition, such as by structure, formula, chemical name, or physical properties, and not merely a wish or plan for obtaining the chemical invention claimed. See, e.g., Univ. of Rochester v. G.D. Searle & Co., 358 F.3d 916, 927, 69 USPQ2d 1886, 1894-95.*

5. Claims 85-87,101 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

There is no support in the specification as originally filed for the method of claim 85 which deletes the term "tertiary structure of the pathogenic self protein is essentially preserved". Regarding applicants comments, the passages of the specification to which applicant refers both contain the aforementioned limitation. Whilst said phrase is indefinite as per the previous Office Action, it still recites a functional limitation of the claimed method that was disclosed in the specification as originally filed. The claim under consideration does not contain said limitation and thus differs in scope from the claimed invention. For example, if said term was interpreted as encompassing the tertiary structure as defined by crystal structure, the claim under consideration no longer requires that crystal structure is essentially preserved and thus differs in scope and is broader in scope from the invention as disclosed in the specification as originally filed.

There is no support in the specification as originally filed for the method of claim 86 which deletes the term "flanking regions". Regarding applicants comments, the passages of the specification to which applicant refers do not address the claimed method absent said limitation. Whilst said term is indefinite as per the previous Office

action, it appears that said term would minimally imply some location in relation to the molecule other than anywhere in the molecule as per encompassed by the new limitation. Thus, the specification as originally filed does not disclose support for the scope of the claimed invention.

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. The rejection of claims 85-87 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention as per the previous Office Action (*Claim 85 is indefinite in the recitation of "the tertiary structure of the pathogenic self-protein is essentially preserved" because it is unclear what this means or encompasses. It is unclear what changes to the tertiary structure would or would not be encompassed by the aforementioned term. For example, it is unclear if this term encompasses changes at the physical/chemical level (eg. crystal structure) or simply functional changes (eg. still immunogenic antigen as evidenced by antibody binding by antibodies specific for unmodified antigen). If the term is interpreted as encompassing changes at the physical/chemical level, it is unclear as to what deviations from the normal crystal structure would or would not be encompassed by the term "essentially preserve the overall tertiary structure". ) and (Claim 86 is indefinite in the recitation of "preserve flanking regions" because it is unclear what this term means or encompasses) are withdrawn in view of the amended claims.*

8. Claims 85-87 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Applicants arguments have been considered and deemed not persuasive.

Claim 85 is indefinite in the recitation of "pathogenic self-protein " because it is unclear what this means or encompasses. Said term is not defined in the specification

and has no art recognized definition. It is unclear if said term applies to mutant versions of normal proteins or normal proteins expressed at abnormal levels or normal proteins that contain epitopes that cross react with exogenous pathogenic proteins or combinations of the aforementioned. Regarding applicants comments about what that said term means, the cited passage of the specification does not clarify the meaning of the aforementioned terms.

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

10. Claims 85 and 86 stand rejected under 35 U.S.C. 102(b) as being anticipated by Russell-Jones et al. (WO 92/05192) as evidenced by Dean et al. (US Patent 5,716,596). Applicants arguments have been considered and deemed not persuasive.

Russell-Jones et al. teach T cell epitopes derived from Trat protein (see Abstract). Russell-Jones et al. teach Trat T cell epitopes are inserted into proteins, wherein the insertion of said peptide increases the antibody response against the protein into which Trat has been inserted (see page 4, lines 24-26 and Abstract). Russell-Jones et al. teach that the Trat peptide is inserted such that the protein still functions as an immunogen. The Trat peptide has been inserted into the immunogen in such a manner as to essentially preserve the overall tertiary structure, because the ability of the immunogen to function as an immunogen is maintained (see page 8, first complete paragraph). Russell-Jones et al. teach that the Trat modified immunogen can be used as a vaccine in a composition containing an adjuvant such as saponin (see page 8 and 13). Russell-Jones et al. teach that using recombinant DNA technology that Trat peptide can be inserted into the immunogen via substituting Trat peptide for a peptide contained in said molecule (see page 32 and page 31, first incomplete paragraph). Said insertion would preserve flanking regions on both sides of the Trat T



cell epitope. Russell-Jones et al. teach that immunogens used in the aforementioned vaccines can include self proteins such as luteinizing hormone, somatostatin, inhibin, FSH (see page 9 and claim 12). Russell-Jones et al. teach that such vaccines can be used in animals and humans. Whilst the term "pathogenic self protein" is indefinite, for the purposes of this rejection it will be interpreted as encompassing a normal protein related to a disease. Somatostatin is inherently a "pathogenic self protein" in view of its art recognized role in a variety of diseases (see Dean et al., column 2, first paragraph and column 6, third paragraph from bottom).

Regarding applicants comments about "self proteins", Russell-Jones et al. teaches that the claimed invention can be used as a vaccine in humans (see page 33) and can be used to raise antibody responses against such proteins as luteinizing hormone, somatostatin, inhibin, FSH (eg. self proteins). Whilst the term "pathogenic self protein" is indefinite, for the purposes of this rejection it will be interpreted as encompassing a normal protein related to a disease. Somatostatin is inherently a "pathogenic self protein" in view of its art recognized role in a variety of diseases (see Dean et al., column 2, first paragraph and column 6, third paragraph from bottom). Russell-Jones et al. teach that, "The at least one "immunogen" which forms part of the complex *is any molecule which it is desirable to use to raise an immune response.*". Regarding applicants comments about somatostatin, there is no evidence of record that the invention of Russell-Jones et al. lacks enablement regarding this particular embodiment. The prior art is considered enabled in the absence of evidence to the contrary.

Regarding applicants comments, Russell-Jones et al. teach that their invention encompasses vaccines for use in animals and humans (see page 33). Russell-Jones et al. teach that one such immunogen could include luteinizing hormone or somatostatin or FSH or inhibin (see page 9). Said proteins could only be of two different origins (human or nonhuman). Thus, based on the disclosure of Russell-Jones et al., one of ordinary skill in the art would at once envisage use of human self-protein as a vaccine as per page 33 of Russell-Jones. Russell-Jones et al. teach that T cell epitopes are inserted into proteins, wherein the insertion of said peptide increases the antibody response

against the protein into which Trat has been inserted (see page 4, lines 24-26, page 31, lines 4-8, claim 14 and Abstract). Russell-Jones et al. teach that the Trat peptide is inserted such that the protein still functions as an immunogen. Russell-Jones et al. teach that the Trat modified immunogen can be used as a vaccine in a composition containing an adjuvant such as saponin (see page 8 and 13). Russell-Jones et al. teach that using recombinant DNA technology that Trat peptide can be inserted into the immunogen via substituting Trat peptide for a peptide contained in said molecule (see page 31, first incomplete paragraph and claim 14 wherein the nucleic acid of claim 14 is used to recombinantly produce said protein). Russell-Jones et al. teach that immunogens used in the aforementioned vaccines can include self proteins such as luteinizing hormone, somatostatin, inhibin, FSH (see page 9 and claim 12).

Russell-Jones et al. teach that such vaccines can be used in animals and humans.

Regarding applicants comments and the Travers and Zinkernagel declarations, said declarations have been addressed in the previous Office actions.

11. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

12. Claims 85-87 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Russell-Jones et al. (WO 92/05192) in view of Dean et al. (US Patent 5,716,596).

Russell-Jones et al. teach T cell epitopes derived from Trat protein (see Abstract). Russell-Jones et al. teach Trat T cell epitopes are inserted into proteins, wherein the insertion of said peptide increases the antibody response against the protein into which Trat has been inserted (see page 4, lines 24-26 and Abstract). Russell-Jones et al. teach that the Trat peptide is inserted such that the protein still functions as an immunogen. The Trat peptide has been inserted into the immunogen in such a manner as to essentially preserve the overall tertiary structure, because the ability of the immunogen to function as an immunogen is maintained (see page 8, first complete paragraph). Russell-Jones et al. teach that the Trat modified immunogen can be used as a vaccine in a composition containing an adjuvant such as saponin (see page 8 and 13). Russell-Jones et al. teach that using recombinant DNA technology that Trat peptide can be inserted into the immunogen via substituting Trat peptide for a peptide contained in said molecule (see page 32 and page 31, first incomplete paragraph). Said insertion would preserve flanking regions on both sides of the Trat T cell epitope. Russell-Jones et al. teach that immunogens used in the aforementioned vaccines can include self proteins such as luteinizing hormone, somatostatin, inhibin, FSH (see page 9 and claim 12). Russell-Jones et al. teach that such vaccines can be used in animals and humans. Whilst the term "pathogenic self protein" is indefinite, for the purposes of this rejection it will be interpreted as encompassing a normal protein related to a disease. Somatostatin is a "pathogenic self protein" in view of its art recognized role in a variety of diseases (see Dean et al., column 2, first paragraph and column 6, third paragraph from bottom). Russell-Jones et al. do not teach use of immunodominant foreign T cell epitopes derived from diphtheria toxoid. Russell-Jones teach that immunodominant foreign T cell epitopes derived from diphtheria toxoid were known in the art (see page 4, first paragraph). Russell-Jones et al. teach that diphtheria toxoid has already been approved for use as a carrier for human vaccines (see page 14, first paragraph). It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have created the claimed invention because Russell-Jones et al. teach the claimed method except for use of immunodominant

foreign T cell epitopes derived from diphtheria toxoid, Russell-Jones et al. teach that immunodominant foreign T cell epitopes derived from diphtheria toxoid were known in the art and that diphtheria toxoid was already approved as a carrier for human vaccines. One of ordinary skill in the art would have been motivated to do so because immunodominant foreign T cell epitopes derived from diphtheria toxoid were known in the art and diphtheria toxoid was already approved as a carrier for human vaccines.

Regarding applicants comments about "self proteins", Russell-Jones et al. teaches that the claimed invention can be used as a vaccine in humans (see page 33) and can be used to raise antibody responses against such proteins as luteinizing hormone, somatostatin, inhibin, FSH (eg. self proteins). Russell-Jones et al. teach that, "The at least one "immunogen" which forms part of the complex *is any molecule which it is desirable to use to raise an immune response.*". Regarding applicants comments about somatostatin, there is no evidence of record that the invention of Russell-Jones et al. lacks enablement regarding this particular embodiment. The prior art is considered enabled in the absence of evidence to the contrary. Regarding applicants comments, Russell-Jones et al. teach that their invention encompasses vaccines for use in animals and humans (see page 33). Russell-Jones et al. teach that one such immunogen could include luteinizing hormone or somatostatin or FSH or inhibin (see page 9). Said proteins could only be of two different origins (human or nonhuman). Thus, based on the disclosure of Russell-Jones et al., one of ordinary skill in the art would at once envisage use of human self-protein as a vaccine as per page 33 of Russell-Jones. Russell-Jones et al. teach that T cell epitopes are inserted into proteins, wherein the insertion of said peptide increases the antibody response against the protein into which the peptide has been inserted (see page 4, lines 24-26, page 31, lines 4-8, claim 14 and Abstract). Russell-Jones et al. teach that the peptide is inserted such that the protein still functions as an immunogen. Russell-Jones et al. teach that the modified immunogen can be used as a vaccine in a composition containing an adjuvant such as saponin (see page 8 and 13). Russell-Jones et al. teach that using recombinant DNA technology that the peptide can be inserted into the immunogen via substituting the peptide for a peptide contained in said molecule (see page 31, first incomplete paragraph and claim 14 wherein the nucleic acid of claim 14 is used to recombinantly produce said protein). Russell-Jones et al. teach that immunogens used in the

aforementioned vaccines can include self proteins such as luteinizing hormone, somatostatin, inhibin, FSH (see page 9 and claim 12).

Russell-Jones et al. teach that such vaccines can be used in animals and humans.

One of ordinary skill in the art would have been motivated to combine the aforementioned teachings because immunodominant foreign T cell epitopes derived from diphtheria toxoid were known in the art and diphtheria toxoid was already approved as a carrier for human vaccines. Furthermore, in the post KSR Int'l Co. v. Teleflex Inc. universe, motivation per se is not even required in a rejection under 35 USC 103. In KSR Int'l Co. v. Teleflex Inc., 550 U.S. m, 2007 WL 1237837, at \*13 (2007) it was stated that **"if a technique has been used to improve one device, and a person of ordinary skill in the art would recognize that it would improve similar devices in the same way, using the technique is obvious unless its actual application is beyond his or her skill"**.

Regarding applicants comments and the Travers, Schmidt, Borregaard and Zinkernagel declarations, said declarations have been addressed in the previous Office actions.

13. Claim 101 is rejected under 35 U.S.C. 103(a) as being unpatentable over Russell-Jones et al. in view of Dean et al. (US Patent 5,716,596) as applied to claims 85-87 above, and further in view of Hellman (WO 93/05810) and Le et al. (US Patent 5,698,195).

The previous rejection renders obvious the claimed invention except for use of TNF $\alpha$ . Hellman teaches that modulation of self proteins responsible for manifestations of a particular disease can be achieved using self-protein conjugated to a carrier which is recognized by T helper cells(see pages 5-12) and wherein the administered hybrid molecule elicits antibodies against said molecule. Le et al. teach that antibodies against TNF $\alpha$  are used to treat TNF $\alpha$  mediated diseases in humans (see abstract and column 5). It would have been prima facies obvious to one of ordinary skill in the art at the time the invention was made to have created the claimed invention because the use of anti TNF $\alpha$  antibodies to treat TNF $\alpha$  mediated disease was known in the art, Hellman teaches that modulation of self proteins responsible for manifestations of a particular

disease can be achieved by inducing antibodies against said molecules using self molecules that contain T helper epitopes and Russell-Jones et al. teach methods for inducing antibodies against self proteins using Trtat modified molecules.

14. No claim is allowed.

15. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ron Schwadron, Ph.D. whose telephone number is 571 272-0851. The examiner can normally be reached on Monday-Thursday 7:30-6:00 pm.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number:  
08/955,373  
Art Unit: 1644

Page 14

Ron Schwadron, Ph.D.  
Primary Examiner  
Art Unit 1644

  
RONALD D. SCHWADRON  
PRIMARY EXAMINER  
GROUP 1600-1600